In a large population-based cohort study, cholesterol variability was an independent predictor for the development of MI and stroke, as well as for all-cause mortality, in the general population.
Following a TV program on the French-German public network ARTE that denied the proven link between cholesterol levels and CVD, the potential effects of such disinformation are considered.
The method is an adaptation of the Friedwald formula that incorporates a patient-specific TG:VLDL-ratio. Added accuracy is largest in those with LDL-c <70 mg/dL, without added expense.
Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.
The combination of low sodium intake and the DASH diet was associated with significant SBP reductions in patients with a higher baseline level compared with normal diet plus high sodium.
In HFrEF patients with an ICD under remote control, treatment with ARNI decreased ventricular arrhythmias and appropriate ICD shocks as compared to angiotensin inhibition alone.
IDF 2017 Prof Sattar reports on the results of the DiRECT trial evaluating a weight management program with huge implications for clinical practice. Almost half of the patients in the intervention group had remission of T2DM 1 year after the start of the trial.
COMPASS-eligible patients represented a substantial fraction of the spectrum of stable CAD and PAD outpatients from the REACH registry.
In a sub-analysis of the ARIC study, midlife systemic inflammation was associated with the development of chronic microangiopathic structural white matter abnormalities in the elderly.
Notably, new recommendations in the 2018 edition of the ADA Standards of Care reflect advances in diabetes treatment with antidiabetic drugs with CV benefit.
Based on the results of the SUSTAIN trial, semaglutide is approved by the FDA for the treatment of T2DM patients.
The DIRECT trial evaluated a weight management program delivered by primary care. On average, weight reduced by 10 kg and almost half achieved and maintained remission of T2DM at 12 months after starting the intervention.